Lisata Therapeutics, Inc. LSTA

LSTA Company Overview

Lisata Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of targeted therapies intended to improve the delivery and effectiveness of anti-cancer treatments. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on investigational therapeutics designed to enhance penetration of chemotherapeutics and immunotherapies into solid tumors. Its lead product candidate is CEND-1, a peptide-based investigational agent being studied in combination with standard-of-care cancer treatments across multiple solid tumor indications.

The company’s primary business activity is research and development rather than commercial product sales, and its revenue profile has historically been tied to financing activities, licensing arrangements, and collaborations rather than recurring operating revenue. Lisata evolved through a series of corporate restructurings and strategic shifts, including prior operations under different corporate identities before focusing on oncology therapeutics and adopting the Lisata Therapeutics name. The company positions itself around tumor microenvironment modulation and enhanced drug delivery, seeking differentiation through combination-based oncology strategies.